Clinical trials & evidence

WHO is preparing to ration the obesity drug revolution before it becomes another access disaster

CAR-T Starts Moving From Factory Medicine to In-Patient Engineering

AML’s Frontline Future Starts With Finding the Mutation Fast

FSHD Gets a Stronger Biological Signal

ALS Immunotherapy Moves Into the Extension Phase

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care

GIST Care Looks Beyond First-Generation KIT Control
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
